Beam Therapeutics, Inc. (BEAM)
24.50
+0.11
(+0.45%)
USD |
NASDAQ |
Oct 02, 16:00
24.50
0.00 (0.00%)
After-Hours: 20:00
Beam Therapeutics Enterprise Value : 1.624B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.624B |
| October 01, 2026 | 1.613B |
| September 30, 2026 | 1.619B |
| September 29, 2026 | 1.626B |
| September 28, 2026 | 1.597B |
| September 25, 2026 | 1.601B |
| September 24, 2026 | 1.641B |
| September 23, 2026 | 1.611B |
| September 22, 2026 | 1.772B |
| September 21, 2026 | 1.703B |
| September 18, 2026 | 1.671B |
| September 17, 2026 | 1.642B |
| September 16, 2026 | 1.480B |
| September 15, 2026 | 1.492B |
| September 14, 2026 | 1.585B |
| September 11, 2026 | 1.572B |
| September 10, 2026 | 1.611B |
| September 09, 2026 | 1.694B |
| September 08, 2026 | 1.865B |
| September 04, 2026 | 2.157B |
| September 03, 2026 | 2.137B |
| September 02, 2026 | 2.119B |
| September 01, 2026 | 2.091B |
| August 31, 2026 | 2.134B |
| August 28, 2026 | 2.122B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.242B |
| August 26, 2026 | 2.212B |
| August 25, 2026 | 2.299B |
| August 24, 2026 | 2.020B |
| August 21, 2026 | 2.168B |
| August 20, 2026 | 2.026B |
| August 19, 2026 | 2.096B |
| August 18, 2026 | 1.838B |
| August 17, 2026 | 1.893B |
| August 14, 2026 | 1.857B |
| August 13, 2026 | 1.832B |
| August 12, 2026 | 1.853B |
| August 11, 2026 | 1.867B |
| August 10, 2026 | 1.911B |
| August 07, 2026 | 1.932B |
| August 06, 2026 | 1.908B |
| August 05, 2026 | 1.890B |
| August 04, 2026 | 2.022B |
| August 03, 2026 | 1.770B |
| July 31, 2026 | 1.730B |
| July 30, 2026 | 1.830B |
| July 29, 2026 | 1.781B |
| July 28, 2026 | 1.809B |
| July 27, 2026 | 1.683B |
| July 24, 2026 | 1.686B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.352B |
| Twist Bioscience Corp. | 11.75B |
| Prime Medicine, Inc. | 556.00M |
| Q32 Bio, Inc. | 94.38M |
| Sarepta Therapeutics, Inc. | 2.106B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -122.68M |
| Revenue (Quarterly) | 0.49M |
| Total Expenses (Quarterly) | 123.17M |
| EPS Diluted (Quarterly) | -1.176 |
| Gross Profit Margin (Quarterly) | -1.00K% |
| Profit Margin (Quarterly) | -25.04K% |
| Earnings Yield | -3.51% |
| Normalized Earnings Yield | -3.461 |